Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
A Randomized, Double-Blind, Vehicle-Controlled, First-in-Human Safety, Tolerability and Proof-of-Concept Study of Topical ATR12-351 in Adults With Netherton Syndrome
Azitra Inc.
12 participants
Jun 19, 2024
INTERVENTIONAL
Conditions
Summary
The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.
Eligibility
Inclusion Criteria3
- Adults ≥18 years of age
- Confirmed mutation of the serine protease inhibitor of Kazal type 5 (SPINK5) gene
- Involvement of ≥20% of body surface area with skin changes consistent with Netherton syndrome
Exclusion Criteria5
- Use of biologic therapies, antibiotics, antihistamines, corticosteroids, retinoids, disease-modifying antirheumatic drugs (DMARDs), immunosuppressive agents, phosphodiesterase-4 (PDE4) inhibitors, topical calcineurin inhibitors, or topical Janus kinase (JAK) inhibitors
- Open wounds or extensive areas of excoriation precluding identification of appropriate application sites in the Investigator's judgment
- Concurrent involvement in any other clinical study/expanded access program with an investigational drug or device or has participated in a clinical study within 30 days prior to the screening visit
- Residing with an immunocompromised person in the same dwelling from the baseline visit through 2 weeks after the treatment period
- History of ultraviolet phototherapy within the planned treatment area 4 weeks prior to baseline
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06137157